Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference Transcript
Welcome back, everyone, to the 3rd Annual HC Wainwright HVB conference. My name is Patrick Trucchio. I'm a senior biotech analyst at HC Wainwright. My pleasure to introduce our next presenter, Scot Roberts, CSO of Altimmune, a clinical-stage biopharmaceutical company focused on development of novel peptide-based therapeutics for treatment of obesity and liver diseases.
So maybe we can begin first with some discussion around Altimmune's synthetic peptide technology platform. How did it come to be in its current form? And what makes it differentiated from others on the market?
Sure. Well, first of all, thank you for inviting me here, Patrick. It's a pleasure to talk about the HBV program, we call it HepTcell. So to your question, what's the technology and how is it different? So as it relates to HepTcell, and this is unique to that particular asset and not for our obesity or NASH program, the Pemvidutide.
But with respect to HepTcell, the goal
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |